Avanos Medical, Inc.
NYSE•AVNS
CEO: Mr. Michael C. Greiner CPA
セクター: Healthcare
業種: Medical - Devices
上場日: 2014-10-21
Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
連絡先情報
時価総額
$636.63M
PER (TTM)
-9.4
34.4
配当利回り
--
52週高値
$15.68
52週安値
$9.30
52週レンジ
順位60Top 89.2%
2.1
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.1 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$180.90M+0.00%
直近4四半期の推移
EPS
$0.08+0.00%
直近4四半期の推移
フリーCF
$21.30M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Total Net Sales Growth Total Net Sales reached $701.2M, reflecting 1.9% growth compared to $687.8M in 2024, driven by segment performance.
Specialty Nutrition Sales Surge Specialty Nutrition Systems sales grew 9.2% to $432.9M, driven by strong demand for both enteral feeding and neonate solutions.
Operating Loss Significantly Reduced GAAP Operating Loss narrowed to $(61.6)M from $(396.2)M, largely due to a substantial reduction in goodwill impairment charges.
Nexus Acquisition Completed Completed Nexus Acquisition in September 2025 for $27.0M, enhancing the strategic Specialty Nutrition Systems portfolio offerings.
リスク要因
Competition and Obsolescence Risk Intense competition and rapid technological advances risk making current products obsolete or less competitive quickly across markets.
Global Trade and Tariffs Impact Reliance on Mexico manufacturing subjects operations to tariffs; new trade restrictions increase product costs and disrupt supply chains.
Reimbursement Coverage Uncertainty Uncertainty regarding Medicare coverage for RFA treatments, with a final determination expected early 2026, could reduce sales.
AI Integration Challenges Ineffective integration of new AI technology risks operational inefficiencies, reputational damage, and increased investment costs.
見通し
Transformation Process Continues Restructuring initiatives, including organizational alignment, are expected to continue through 2026 for ongoing profitability enhancement.
Restructuring Savings Expected Anticipated annualized cost savings from restructuring initiatives range from $15.0M to $20.0M upon full implementation.
Focus on Core Segments Strategy remains focused on advancing core SNS and PM&R segments following recent divestiture and asset sales activities.
Capital Needs Anticipated Company may seek additional debt or equity financing to fund ongoing research, development activities, and future acquisitions.
同業比較
売上高 (TTM)
$12.49B
$854.40M
$822.31M
粗利益率 (最新四半期)
100.0%
83.5%
73.2%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| BFLY | $967.60M | -12.5 | -35.3% | 6.9% |
| AVNS | $636.63M | -9.4 | -8.6% | 12.0% |
| BVS | $577.34M | 25.3 | 13.8% | 45.5% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
2.6%
緩やかな成長
4四半期純利益CAGR
-17.5%
収益性の低下
キャッシュフロー安定性
100%
優れたキャッシュフローの実績
深度リサーチ
次回決算:2026年5月4日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし